Amarin - The Science Of Lipid Therapy (Seite 71)
eröffnet am 03.01.14 20:10:32 von
neuester Beitrag 12.06.24 08:04:07 von
neuester Beitrag 12.06.24 08:04:07 von
Beiträge: 1.846
ID: 1.190.027
ID: 1.190.027
Aufrufe heute: 5
Gesamt: 156.788
Gesamt: 156.788
Aktive User: 0
ISIN: US0231112063 · WKN: A0NBNG · Symbol: EH3A
0,7781
USD
-3,37 %
-0,0271 USD
Letzter Kurs 15.06.24 Nasdaq
Neuigkeiten
TitelBeiträge |
---|
04.06.24 · globenewswire |
28.05.24 · globenewswire |
06.05.24 · globenewswire |
01.05.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
323,60 | +17,59 | |
8,6600 | +17,03 | |
5,3700 | +15,98 | |
449,10 | +15,09 | |
10,000 | +14,94 |
Wertpapier | Kurs | Perf. % |
---|---|---|
2,1000 | -16,00 | |
2,0525 | -17,40 | |
7,1900 | -20,02 | |
0,9500 | -22,76 | |
80,22 | -23,42 |
Beitrag zu dieser Diskussion schreiben
Klar, irgendein Idiot muss ja jetzt die Papiere, mit denen man sich verzockt hat, abnehmen, da soll es jezt Europa richten, weil hier alle auf Fischölkapseln warten 😅😅😅
Abwarten Arschgeige:
Amarin focus shifts to EU opportunity after patent ruling, says Piper Sandler 11:25 AMRN Piper Sandler analyst Yasmeen Rahimi said the news that the Federal Circuit Court of Appeals has already affirmed the District Court's invalidation of Vascepa's patents took her by surprise in terms of the quick turnaround following oral arguments yesterday, but she thinks today's response in terms of stock price "signals that the appeals ruling was likely regarded as a call option." With the "bandaid ripped off," value investors appreciate the significant EU opportunity for Vascepa and may be focused on a potential takeout, said Rahimi, who also sees investors recognizing "the hard truth that Vascepa's sales are not going to immediately go to zero." The analyst keeps an Overweight rating on Amarin shares with a $21 price target.
Read more at:
https://thefly.com/n.php?id=3155756
Amarin focus shifts to EU opportunity after patent ruling, says Piper Sandler 11:25 AMRN Piper Sandler analyst Yasmeen Rahimi said the news that the Federal Circuit Court of Appeals has already affirmed the District Court's invalidation of Vascepa's patents took her by surprise in terms of the quick turnaround following oral arguments yesterday, but she thinks today's response in terms of stock price "signals that the appeals ruling was likely regarded as a call option." With the "bandaid ripped off," value investors appreciate the significant EU opportunity for Vascepa and may be focused on a potential takeout, said Rahimi, who also sees investors recognizing "the hard truth that Vascepa's sales are not going to immediately go to zero." The analyst keeps an Overweight rating on Amarin shares with a $21 price target.
Read more at:
https://thefly.com/n.php?id=3155756
...aber dafür keine Euros mit der Fischbüchse verloren 🤠
Antwort auf Beitrag Nr.: 64.984.503 von dpdwvz am 03.09.20 22:54:13Du hast nach wie vor keine Ahnung!
...wie man hier beschimpft wurde, wenn man auch nur den kleinsten Kritikpunkt äußerte, da wurden lieber Traumkursziele von 30 Euro ausgegeben. Doch nur Fischbonbons ....;-)
....und deswegen bezweifle ich sehr stark , dass ein Berufungsverfahren ( falls überhaupt zulässig ) erfolgreich sein wird....
Amarin wurde von hinten bis vorne beschissen, traurig aber wahr, scheiß USA, passt zu Trump......
Antwort auf Beitrag Nr.: 64.980.753 von bernie55 am 03.09.20 17:52:33ob das wirklich was bringt?
Der Ansatz mit einem eigenen Generika gefällt mir schon viel besser 😎
Wurde hier sicher schonmal diskutiert.
Seit YTD hat der Kurs % Chg -77.33 verloren.
Wie hoch schätz man denn den Umsatzverlust durch die Generikas?
Ist dieser starke Kursverlust wirklich gerechtfertigt?
Der Ansatz mit einem eigenen Generika gefällt mir schon viel besser 😎
Wurde hier sicher schonmal diskutiert.
Seit YTD hat der Kurs % Chg -77.33 verloren.
Wie hoch schätz man denn den Umsatzverlust durch die Generikas?
Ist dieser starke Kursverlust wirklich gerechtfertigt?
Antwort auf Beitrag Nr.: 64.980.468 von bernie55 am 03.09.20 17:37:20Ich weiß nicht , warum dieser Berufungs-Schritt jetzt angedacht wird.
Was bewegt AMRN, diesen Schritt zu gehen ?
Glaubt AMRN wirklich noch an das "Wunder von Bern" ?
Und überhaupt : DARF AMRN noch in Revision gehen ? - in den USY Foren wird von "Ruling 36" gesprochen, Meaning no more appeals !!! .
Was bewegt AMRN, diesen Schritt zu gehen ?
Glaubt AMRN wirklich noch an das "Wunder von Bern" ?
Und überhaupt : DARF AMRN noch in Revision gehen ? - in den USY Foren wird von "Ruling 36" gesprochen, Meaning no more appeals !!! .
Amarin wird Berufungsgerichtsentscheid zu Vascapa-Patenten anfechten
Amarin to contest appeals court decision on Vascapa patents :
Sep. 03, 2020 11:24 AM ETAmarin Corporation plc (AMRN)By: Douglas W. House, SA News Editor
Amarin (AMRN -3.7%) is not yet admitting defeat in its patent infringement litigation against would-be generic Vascepa competitors Dr. Reddy's Laboratories (RDY -0.2%) and Hikma Pharmaceuticals.
Within 30 days, it plans to file a petition for an en banc review of the U.S. Court of Appeals for the Federal Circuit panel decision upholding a Nevada court ruling in favor of the above two generic drug firms. An en banc review allows the full circuit court of 12 judges to potentially overturn a decision from the three three-judge panel.
CEO John Thero says, “We are extremely disappointed with today’s ruling and plan to vigorously pursue available remedies. Importantly, we and our partners are continuing to pursue additional regulatory approvals for VASCEPA in China, Europe and the additional countries in the Middle East, and remain confident in the global market potential of VASCEPA. We are particularly excited about the anticipated commercialization opportunities for VASCEPA in Europe as we prepare for expected approval and launch in early 2021. At the same time, we will continue to meet the strong demand for VASCEPA here in the United States through our proven manufacturing capabilities.
”In a statement, Hikma says it received the FDA (conditional) nod in May and is now preparing for commercial launch.
https://seekingalpha.com/news/3611512
Amarin to contest appeals court decision on Vascapa patents :
Sep. 03, 2020 11:24 AM ETAmarin Corporation plc (AMRN)By: Douglas W. House, SA News Editor
Amarin (AMRN -3.7%) is not yet admitting defeat in its patent infringement litigation against would-be generic Vascepa competitors Dr. Reddy's Laboratories (RDY -0.2%) and Hikma Pharmaceuticals.
Within 30 days, it plans to file a petition for an en banc review of the U.S. Court of Appeals for the Federal Circuit panel decision upholding a Nevada court ruling in favor of the above two generic drug firms. An en banc review allows the full circuit court of 12 judges to potentially overturn a decision from the three three-judge panel.
CEO John Thero says, “We are extremely disappointed with today’s ruling and plan to vigorously pursue available remedies. Importantly, we and our partners are continuing to pursue additional regulatory approvals for VASCEPA in China, Europe and the additional countries in the Middle East, and remain confident in the global market potential of VASCEPA. We are particularly excited about the anticipated commercialization opportunities for VASCEPA in Europe as we prepare for expected approval and launch in early 2021. At the same time, we will continue to meet the strong demand for VASCEPA here in the United States through our proven manufacturing capabilities.
”In a statement, Hikma says it received the FDA (conditional) nod in May and is now preparing for commercial launch.
https://seekingalpha.com/news/3611512
04.06.24 · globenewswire · Amarin |
28.05.24 · globenewswire · Amarin |
06.05.24 · globenewswire · Amarin |
01.05.24 · globenewswire · Amarin |
24.04.24 · globenewswire · Amarin |
22.04.24 · globenewswire · Amarin |
15.04.24 · globenewswire · Amarin |
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 08.04.24 · globenewswire · Amarin |
06.04.24 · globenewswire · Amarin |
03.04.24 · globenewswire · Amarin |